Obinutuzumab Beta Combined With Low-dose Glucocorticoid in New-onset ANCA-Associated Glomerulonephritis

Starting soon · Phase 2

Conditions studied: ANCA-Associated Glomerulonephritis (AAGN), ANCA-Associated Vasculitis (AAV)

In brief

This study is an open-label, single-arm, exploratory study designed to evaluate the efficacy and safety of Obinutuzumab beta combined with a rapid-tapering glucocorticoid regimen in patients with new-onset ANCA-associated glomerulonephritis (AAGN).

Key facts

Study ID
NCT07746180
Run by
Chinese PLA General Hospital
People needed
20
Starts
2026-07-31
Expected to finish
2029-03-30
Last updated by the study team
2026-08-04

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.